Vir Biotechnology Inc. (VIR) Prices 7.14M Share Common Offering at $42/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
July 7, 2020 10:24 PM EDTSAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the pricing of its previously announced underwritten public offering of 7,142,857 shares of its common stock at a price to the public of $42.00 per share. The gross proceeds to Vir from the offering before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $300.0 million. The offering is expected to close on July 10, 2020, subject to satisfaction of customary closing conditions. In addition, Vir has... More
